胺碘酮联合美托洛尔治疗慢性心力衰竭并室性心律失常疗效和安全性分析

Analysis of Efficacy and Safety of Amiodarone Combined with Metoprolol in the Treatment of Chronic Heart Failure and Ventricular Arrhythmia

目的探讨胺碘酮联合美托洛尔治疗慢性心力衰竭(CHF)并室性心律失常(VA)的临床疗效与安全性。方法方便选取2015年2月—2016年3月该院心内科收治的86例CHF并VA患者作为研究对象,将其随机分配为观察组与对照组,每组各43例,两组均给予常规抗心衰治疗,对照组采用美托洛尔治疗,观察组在此基础上加用胺碘酮,比较两组临床疗效与治疗安全性。结果两组比较,观察组治疗总有效率为97.67%,明显高于对照组的81.40%,差异有统计学意义(χ~2=7.295,P<0.05)。结合患者自我感觉、体格检查、心电图、肝功能化验结果进行安全性评价,结果显示两组不良反应发生率相似(4.65%vs6.98%),差异无统计学意义(χ~2=0.056,P>0.05)。结论胺碘酮联合美托洛尔治疗慢性心力衰竭并室性心律失常疗效确切,而且不会增加不良反应,安全性值得肯定,推荐在临床上使用。

Objective This paper tries to investigate the clinical efficacy and safety of amiodarone combined with metoprolol in the treatment of chronic heart failure（CHF） and ventricular arrhythmia（VA）. Methods 86 patients with CHF and VA who were admitted to the Department of Cardiology in the hospital from February 2015 to March 2016 were convenient selected and randomly assigned to the observation group and the control group, 43 cases in each group. Both groups were given routine anti-cardiac therapy. The patients in the control group were treated with metoprolol and the observation group was treated with amiodarone. The clinical efficacy and safety of the two groups were compared. Results Compared with the two groups, the total effective rate in the observation group was 97.67%, which was significantly higher than that in the control group（81.40%）. There was a significant difference after（χ~2=7.295, P〈0.05）. Combined with patient self-feeling, physical examination, electrocardiogram, liver function test results for safety evaluation, the results showed that the incidence of adverse reactions in the two groups was similar（4.65% vs 6.98%）, and there was no significant difference（χ~2=0.056, P〉0.05）.Conclusion Amiodarone combined with metoprolol is effective in the treatment of chronic heart failure and ventricular arrhythmia, and does not increase adverse reactions. The safety is worthy of recognition and is recommended for clinical use.